SOUTH SAN FRANCISCO, Calif.,
Feb. 27, 2014 /PRNewswire/ -- Rigel
Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that company
management will present at two upcoming investor conferences.
Details of the events are as follows:
Cowen and Company 34th Annual Health Care
Conference
Date – March 3, 2014 at 2:50 p.m. ET
Location – Boston, MA
Presenter – Ryan Maynard, Executive
Vice President and Chief Financial Officer
26th Annual ROTH Conference
Date – March 11, 2014 at 2:00 p.m. PT
Location – Dana Point, CA
Presenter – James M. Gower. Chairman
and Chief Executive Officer
Both events will be webcast live and can we accessed at
www.rigel.com. Please connect to Rigel's website several
minutes prior to the start of the live webcast to ensure adequate
time for any software download that may be necessary.
About Rigel (www.rigel.com)
Rigel Pharmaceuticals,
Inc. is a clinical-stage drug development company that
discovers and develops novel, small-molecule drugs for the
treatment of inflammatory and autoimmune diseases, as well as
muscle disorders. Rigel's pioneering research focuses on
intracellular signaling pathways and related targets that are
critical to disease mechanisms. The Company currently has five
product candidates in development: fostamatinib, an oral SYK
inhibitor expected to enter Phase 3 clinical trials for ITP and a
Phase 2 clinical trial for IgA nephropathy in the first half of
2014; R348, a topical JAK/SYK inhibitor currently in Phase 2
clinical trials for dry eye; R118, an AMPK activator entering Phase
1 in early 2014; and two oncology product candidates in Phase 1
development with partners BerGenBio and Daiichi Sankyo.
Contact: Ryan Maynard
Phone: 650.624.1284
Email: invrel@rigel.com
SOURCE Rigel Pharmaceuticals, Inc.